Research Principles
Global comparability · Compliant and traceable data · Quantitative analysis as the primary approach · Continuous, phased refinement
BIU develops rankings and indices that help stakeholders understand brand strength, innovation, trust, and market recognition. Explore the latest evaluation results and project information below.
Search TopGBR's brand competitiveness evaluation results for listed innovative pharmaceutical companies worldwide by company name, keyword or stock code.
Evaluation reference date: .
Initiated by the Brand Intelligence Unit (BIU) of the Department of Marketing at City University of Hong Kong and led by Prof. YANG Zhilin, the project leverages Hong Kong's position as an international hub and focuses on pharmaceuticals, biotechnology, medical devices, and healthcare services. It is developing a scientifically rigorous, traceable and continuously evolving brand evaluation framework to provide professional brand-value benchmarks for organizations worldwide.
Global comparability · Compliant and traceable data · Quantitative analysis as the primary approach · Continuous, phased refinement
The first phase focuses on publicly listed innovative pharmaceutical companies worldwide, covering sample research, model calibration and publication of the rankings.
Long-term brand benchmarks for companies · Data support for decision-makers · Support for industry development
The TopGBR Global Healthcare and Life Sciences Brand Rankings project was launched at BIOHK2026, the Hong Kong International Biotechnology Conference & Exhibition, on 11 September 2026.
BIU prioritizes transparency, methodological consistency, and responsible communication. Ranking results are released after data sources, criteria, and validation procedures are ready for public release.